
    
      This is a multi-center, randomized, placebo-controlled, double-masked, parallel-group study.
      Subjects will be randomized into three treatment groups: 0.005%, or 0.01% Lacripepâ„¢, or
      placebo in a 1:1:1 ratio.
    
  